Company Profile
Senti Biosciences Stock Price, News & Analysis
- Ticker:
- SNTI
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.36 USD (-3.78%)
Close
Last updated: August 6, 2026
30.6M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, SNTI closed down 3.78% at $0.3589. No new same-company headline was identified in the current news window.
Company overview
Gene Circuit Cell Therapy Company
Senti Biosciences uses a proprietary Gene Circuit platform to develop next-generation cell and gene therapies. Its logic-gated designs are intended to increase selective tumor-cell killing while protecting healthy tissue.
SENTI-202 Logic-Gated CAR-NK
SENTI-202 is an off-the-shelf CAR-NK candidate designed to target hematologic malignancies expressing CD33 and/or FLT3 while using an EMCN NOT gate to protect healthy hematopoietic stem and progenitor cells. An IL-15 release module is intended to improve CAR-NK persistence, expansion, and activity.
Registrational Path in AML
Senti Bio completed a Type B Initial Comprehensive Multidisciplinary RMAT meeting with the FDA and aligned on pivotal clinical and CMC strategy for SENTI-202. FDA feedback supports the potential use of a single-arm, multicenter pivotal trial in relapsed or refractory AML.
Allogeneic Manufacturing Strategy
SENTI-202 is being developed as an off-the-shelf product manufactured from selected donor material. Senti’s Donor X strategy is intended to improve consistency in potency, expansion, and clinical activity across production campaigns.
Logic-Gate Architecture
The OR gate enables recognition of either CD33 or FLT3 on malignant cells, while the EMCN NOT gate is intended to protect healthy hematopoietic cells. This combination illustrates how Senti’s Gene Circuit platform integrates multiple biological signals into a single cell therapy.
Future catalysts
SENTI-202 is expected to advance into a single-arm, multicenter pivotal trial in relapsed or refractory AML to support potential registration.
More complete Phase 1 data, particularly efficacy and MRD-negative responses under the Donor X manufacturing strategy, will inform execution of the pivotal program.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Senti Biosciences (SNTI)?
Senti Biosciences (SNTI) most recently closed at 0.36 USD, a -3.78% move versus the previous session.
What is the market cap of Senti Biosciences (SNTI)?
Senti Biosciences currently has a market capitalization of 30.6M USD on BioPharmSignal.
What does Senti Biosciences do?
Gene Circuit Cell Therapy Company Senti Biosciences uses a proprietary Gene Circuit platform to develop next-generation cell and gene therapies. Its logic-gated designs are intended to increase selective tumor-cell killing while protecting healthy tissue. SENTI-202 Logic-Gated CAR-NK SENTI-202 is an off-the-shelf CAR-NK candidate designed to target...
On which exchange is SNTI stock listed?
Senti Biosciences (SNTI) is associated with NASDAQ, United States, Biopharma.
What is SENTI-202?
SENTI-202 is expected to advance into a single-arm, multicenter pivotal trial in relapsed or refractory AML to support potential registration.
Which conditions is Senti Biosciences targeting with SENTI-202?
SENTI-202 is expected to advance into a single-arm, multicenter pivotal trial in relapsed or refractory AML to support potential registration.
How does Senti Biosciences describe recent progress with SENTI-202?
SENTI-202 is expected to advance into a single-arm, multicenter pivotal trial in relapsed or refractory AML to support potential registration.
What is CAR-NK?
SENTI-202 Logic-Gated CAR-NK SENTI-202 is an off-the-shelf CAR-NK candidate designed to target hematologic malignancies expressing CD33 and/or FLT3 while using an EMCN NOT gate to protect healthy hematopoietic stem and progenitor cells.